Why Conduct a Disinfectant Efficacy Testing DET Study?
Why Conduct a Disinfectant Efficacy Testing (DET) Study?
Introduction
The biocides used in a facility’s contamination control program require validation that extends beyond product label claims.
This validation is essential to ensure effectiveness under actual facility conditions, making it a crucial component of a contamination control strategy for the aseptic pharmaceutical, biopharmaceutical (including cell and gene therapy), and medical device industries.
Conducting Disinfectant Efficacy Testing (DET) is driven by a combination of internal quality processes and global regulatory expectations, including Annex 1 of the EudraLex, Good Manufacturing Practices (GMP) Guidelines and the U.S. Food & Drug Administration (FDA), Guidance for Industry Sterile Drug Products Produced by Aseptic Processing.
The data provided by these DET studies ensures that the contamination control programs for classified areas are compliant and scientifically sound.
What is Disinfectant Efficacy Testing?
Disinfectant Efficacy Testing consists of in vitro laboratory studies, designed to evaluate the effectiveness of sanitizing agents, chemical disinfectants, and sporicidal agents on material coupons representative of facility-specific surfaces.
The chemistries/biocides chosen for testing are used in critical areas as a part of the facility’s contamination control program.
DET qualifies a wet contact time under worst-case conditions, assessing efficacy against both reference-strain microorganisms and microorganisms recovered and retained from the facility’s Environmental Monitoring (EM) program.
What are the Regulatory Expectations Within the Aseptic Manufacturing Industry?
Additionally, the U.S. FDA, Guidance for Industry Sterile Drug Products Produced by Aseptic Processing states, “The suitability, efficacy, and limitations of disinfecting agents and procedures should be assessed.
The effectiveness of these disinfectants and procedures should be measured by their ability to ensure that potential contaminants are adequately removed from surfaces.”2.
The U.S. Environmental Protection Agency (EPA) registration testing for disinfectant manufacturers does not evaluate how disinfectants are used in practice.
As emphasized in USP <1072> Disinfectants and Antiseptics, DET studies are necessary because critical processes, like the disinfection of aseptic areas, require validation.3
What are the Consequences of Failing to Validate the Disinfection Process?
Without supporting data, there is no assurance that the biocides used in the current contamination control program effectively inactivate microorganisms on representative surfaces.
Understanding the limitations and efficacy profiles of the biocides utilized will help determine their appropriate use and support a robust contamination control program.
What Elements Should be Considered when Designing a Disinfectant Efficacy Testing Study?
The design of a DET study, specifically the variable selection, shapes the matrix of the study and is critical to having a successful outcome.
Multiple elements should be considered and selected based on the specific testing needs for the facility.
Risk assessments are essential for determining the best choices for key study variables, such as microorganisms and surface materials.
A test matrix should be robust while also reducing unnecessary testing.
Key Study Variables:
- Biocides
- Microorganisms (facility isolates and reference strains)
- Surface Materials
- Contact Time
- Aging/Expiry Testing
- Exposure Temperature (e.g. increased regulatory expectations around generating data for cold rooms, if found in classified areas)
Conclusion
Validating the efficacy of biocides used in a contamination control program is paramount for the aseptic manufacturing industry.
This validation demonstrates that disinfectants are effective under representative conditions and supports a robust contamination control strategy.
DET is not only driven by global regulatory expectations but by the practical need to ensure that each biocide is appropriate for use in an individual facility.
Implementing DET studies safeguards product quality and patient safety and supports regulatory compliance.
References
- EudraLex-Volume 4 Good Manufacturing Practices (GMP) Guidelines, Annex 1 Manufacture of Sterile Medicinal Products, August, 2022.
https://www.gmp-compliance.org/files/guidemgr/20220825_gmp-an1_en_0.pdf. - FDA Guideline for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Process, September 2004. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.
- General Chapter 1072: Disinfectants and Antiseptics (Revised 2023). USP 26/NF 21; U.S. Pharmacopeia: 2003. www.usp.org.
- U.S. Food & Drug Administration, Issuing Office: Center for Drug Evaluation and Research (CDER). 483 Warning Letter: 696742. ProRx, LLC(March 4, 2025). Retrieved April 2, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-696742-03042025